相关实验视频
Updated: Jun 3, 2025

09:36
Isolated Pancreatic Islet Treatment and Apoptosis Measurement
Published on: May 2, 2025
266
在1型糖尿病中,ISG15会增加β细胞的亡
Jie Liu1, Mei-Qi He1, Gao-Peng Guan1
1Department of Endocrinology, The Third Xiangya Hospital, Central South University, 410007 Changsha, Hunan, China.
Cellular signalling
|January 7, 2025
概括
干扰素刺激基因15 (ISG15) 在1型糖尿病 (T1D) 患者和动物模型中升高. 高水平的ISG15促进β细胞的亡并损害胰岛素分泌,这表明ISG15是T1D的治疗点.
科学领域:
- 免疫学 免疫学 免疫学
- 内分泌学 在内分泌学.
- 病毒学 病毒学
背景情况:
- 1型糖尿病 (T1D) 涉及胰岛素生成β细胞的自身免疫破坏,通常是由容易感染的个体的病毒感染引发的.
- 干扰素刺激基因15 (ISG15) 在病毒感染引起的β细胞损伤中的作用仍然不清楚,尽管感染后其水平增加.
研究的目的:
- 为了研究ISG15在1型糖尿病的发病过程中的临床和细胞作用.
- 阐明ISG15影响β细胞功能和生存的机制.
主要方法:
- 在T1D患者的外周血液和T1D动物模型的胰腺小岛中测量ISG15水平.
- 培养的MIN6β细胞与病毒模仿 (多元I:C)) 刺激了超级生物,并评估了ISG15表达,细胞活力和功能.
- 研究了ISG15对胰岛素分泌和β细胞亡的直接作用.
主要成果:
- 在T1D患者的血液和胰腺小岛中观察到ISG15水平升高.
- 暴露于病毒模仿剂诱导了MIN6细胞中的ISG15上调,抑制了它们的功能和活力.
- 增加的ISG15直接抑制了胰岛素分泌,并促进了TNF-α依赖的β细胞亡.
结论:
- ISG15通过诱导β细胞亡和损害胰岛素分泌,在T1D病变发生中发挥着重要作用.
- 针对ISG15可能为1型糖尿病治疗提供一种新的治疗策略.
相关概念视频
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166

